My burning issues in aggressive Non Hodgkin’s Lymphoma

My burning issues in aggressive Non Hodgkin’s Lymphoma special report memo (2018) 11:109–111 https://doi.org/10.1007/s12254-018-0413-1 David Fuchs · Michael A. Fridrik Received: 29 January 2018 / Accepted: 24 April 2018 / Published online: 28 May 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 Summary Combined-modality treatment with compared to historical controls, and most impor- chemo-immunotherapy and radiotherapy produces tantly, a high percentage (40%) of durable remissions excellent outcomes in early-stage, non-bulky diffuse after one year of follow-up. As in other advances in large B-cell lymphoma, and reducing toxicity of ther- immunotherapy, toxicity is a major concern. Cytokine apy is a major concern, especially in elderly patients. release syndrome occurs frequently (1–18% grade 3–4) In a recent trial, elderly patients with non-bulky and management is complex, sometimes requiring (<7.5 cm) in complete metabolic remission after four admission to intensive care and often including the courses of therapy (rituximab, cyclophosphamide, interleukin-6 receptor antibody tocilizumab. doxorubicine, vincristine, prednisone [R-CHOP-14] based) were spared additional chemotherapy and Keywords Lymphoma, Large B-cell, diffuse · Lym- went on to receive four cycles of rituximab only, while phoma, B-Cell · Radiotherapy · Immunotherapy · Lym- all other patients continued on chemo-immunother- phoma apy. The 2-year overall survival was 98%, which matches historical controls. In http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

My burning issues in aggressive Non Hodgkin’s Lymphoma

Loading next page...
 
/lp/springer_journal/my-burning-issues-in-aggressive-non-hodgkin-s-lymphoma-1g5oGRXsJr
Publisher
Springer Vienna
Copyright
Copyright © 2018 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
D.O.I.
10.1007/s12254-018-0413-1
Publisher site
See Article on Publisher Site

Abstract

special report memo (2018) 11:109–111 https://doi.org/10.1007/s12254-018-0413-1 David Fuchs · Michael A. Fridrik Received: 29 January 2018 / Accepted: 24 April 2018 / Published online: 28 May 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 Summary Combined-modality treatment with compared to historical controls, and most impor- chemo-immunotherapy and radiotherapy produces tantly, a high percentage (40%) of durable remissions excellent outcomes in early-stage, non-bulky diffuse after one year of follow-up. As in other advances in large B-cell lymphoma, and reducing toxicity of ther- immunotherapy, toxicity is a major concern. Cytokine apy is a major concern, especially in elderly patients. release syndrome occurs frequently (1–18% grade 3–4) In a recent trial, elderly patients with non-bulky and management is complex, sometimes requiring (<7.5 cm) in complete metabolic remission after four admission to intensive care and often including the courses of therapy (rituximab, cyclophosphamide, interleukin-6 receptor antibody tocilizumab. doxorubicine, vincristine, prednisone [R-CHOP-14] based) were spared additional chemotherapy and Keywords Lymphoma, Large B-cell, diffuse · Lym- went on to receive four cycles of rituximab only, while phoma, B-Cell · Radiotherapy · Immunotherapy · Lym- all other patients continued on chemo-immunother- phoma apy. The 2-year overall survival was 98%, which matches historical controls. In

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: May 28, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off